Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Steuber

Showing results (51-60 of 209) with videos related to

Pageof 21
Sort By:
International Journal of Cancer|August 14, 2012
Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancersJulia Müller, Arne Ehlers, Lia Burkhardt, et al.
Cancers|March 11, 2023
A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate CancerFrancesco Gentile, Evelina La Civita, Bartolomeo Della Ventura, et al.
Clinical & Experimental Metastasis|January 30, 2025
Incisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care?Giovanni Mazzucato, Fabian Falkenbach, Jonas Ekrutt, et al.
The Journal of Urology|September 24, 2021
Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect LesionsMykyta Kachanov, Sami-Ramzi Leyh-Bannurah, Matthew J Roberts, et al.
Urologic Oncology|July 1, 2015
Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validationJens Hansen, Andreas Becker, Luis A Kluth, et al.
The Prostate|March 24, 2018
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrenceRaisa S Pompe, Philipp Gild, Pierre I Karakiewicz, et al.
Cancer|October 15, 2008
Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lowerJochen Walz, Alexander Haese, Vincenzo Scattoni, et al.
Cells|September 14, 2019
Detection of Androgen Receptor Variant 7 (<i>ARV7)</i> mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate CancerClaudia Hille, Tobias M Gorges, Sabine Riethdorf, et al.
Human Pathology|May 7, 2013
Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrenceMaria Christina Tsourlakis, Michael Schoop, Christoph Plass, et al.
Urology|December 5, 2006
Development and internal validation of preoperative transition zone prostate cancer nomogramThomas Steuber, Felix K-H Chun, Andreas Erbersdobler, et al.
Pageof 21

Showing results (51-60 of 209) with videos related to

Sort By:
Pageof 21
International Journal of Cancer|August 14, 2012
Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancersJulia Müller, Arne Ehlers, Lia Burkhardt, et al.
Cancers|March 11, 2023
A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate CancerFrancesco Gentile, Evelina La Civita, Bartolomeo Della Ventura, et al.
Clinical & Experimental Metastasis|January 30, 2025
Incisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care?Giovanni Mazzucato, Fabian Falkenbach, Jonas Ekrutt, et al.
The Journal of Urology|September 24, 2021
Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect LesionsMykyta Kachanov, Sami-Ramzi Leyh-Bannurah, Matthew J Roberts, et al.
Urologic Oncology|July 1, 2015
Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validationJens Hansen, Andreas Becker, Luis A Kluth, et al.
The Prostate|March 24, 2018
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrenceRaisa S Pompe, Philipp Gild, Pierre I Karakiewicz, et al.
Cancer|October 15, 2008
Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lowerJochen Walz, Alexander Haese, Vincenzo Scattoni, et al.
Cells|September 14, 2019
Detection of Androgen Receptor Variant 7 (<i>ARV7)</i> mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate CancerClaudia Hille, Tobias M Gorges, Sabine Riethdorf, et al.
Human Pathology|May 7, 2013
Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrenceMaria Christina Tsourlakis, Michael Schoop, Christoph Plass, et al.
Urology|December 5, 2006
Development and internal validation of preoperative transition zone prostate cancer nomogramThomas Steuber, Felix K-H Chun, Andreas Erbersdobler, et al.
Pageof 21